Preston Klassen, President & Head of R & D at Regulus Therapeutics Inc. (RGLS), bought 12,000 shares at $7.99 ($96K) on 2025-06-03, disclosed to the SEC on 2025-06-04.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| MTCR | SELL | 2022-04-20 | $22K | — | Filing → |
| MTCR | BUY | 2021-05-20 | $150K | — | Filing → |
| ARNA | SELL | 2019-01-08 | $816K | — | Filing → |